Search research articles
Contact Us
Filters
Showing results (141-150 of 267) with videos related to
Page
of 27
Sort By:
Annals of Internal Medicine
|
January 7, 2015
Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial
Michael Boeckh, W Garrett Nichols, Roy F Chemaly, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 11, 2015
Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations
Harrys A Torres, Pearlie P Chong, Marcos De Lima, et al.
Clinical Transplantation
|
May 25, 2016
Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience
Lakshmikanth Katragadda, Lindsay M McCullough, Yunfeng Dai, et al.
The Journal of Antimicrobial Chemotherapy
|
April 29, 2016
Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial
William W Hope, Thomas J Walsh, Joanne Goodwin, et al.
Transplantation and Cellular Therapy
|
October 12, 2020
Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023
Nosha Farhadfar, Linda J Burns, Tatenda Mupfudze, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 6, 2011
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America
Alison G Freifeld, Eric J Bow, Kent A Sepkowitz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 19, 2005
Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome
Thomas F Patterson, Helen W Boucher, Raoul Herbrecht, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 11, 2011
Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the Center for International Blood and Marrow Transplant Research
Naynesh R Kamani, Shimareet Kumar, Anna Hassebroek, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 21, 2007
Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival
Mary Eapen, Brent R Logan, Dennis L Confer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 10, 2002
Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study
Borje S Andersson, Ashwin Kashyap, Victor Gian, et al.
Page
of 27
Search research articles
Search
Showing results (141-150 of 267) with videos related to
Sort By:
Page
of 27
Annals of Internal Medicine
|
January 7, 2015
Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial
Michael Boeckh, W Garrett Nichols, Roy F Chemaly, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 11, 2015
Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations
Harrys A Torres, Pearlie P Chong, Marcos De Lima, et al.
Clinical Transplantation
|
May 25, 2016
Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience
Lakshmikanth Katragadda, Lindsay M McCullough, Yunfeng Dai, et al.
The Journal of Antimicrobial Chemotherapy
|
April 29, 2016
Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial
William W Hope, Thomas J Walsh, Joanne Goodwin, et al.
Transplantation and Cellular Therapy
|
October 12, 2020
Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023
Nosha Farhadfar, Linda J Burns, Tatenda Mupfudze, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 6, 2011
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America
Alison G Freifeld, Eric J Bow, Kent A Sepkowitz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 19, 2005
Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome
Thomas F Patterson, Helen W Boucher, Raoul Herbrecht, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 11, 2011
Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the Center for International Blood and Marrow Transplant Research
Naynesh R Kamani, Shimareet Kumar, Anna Hassebroek, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 21, 2007
Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival
Mary Eapen, Brent R Logan, Dennis L Confer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 10, 2002
Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study
Borje S Andersson, Ashwin Kashyap, Victor Gian, et al.
Page
of 27